FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2116995045> ?p ?o ?g. }

• W2116995045 endingPage "3861" @default.
• W2116995045 startingPage "3853" @default.
• W2116995045 abstract "The effects of mammalian target of rapamycin (mTOR) inhibition are limited by feedback reactivation of receptor tyrosine kinase signaling in phosphatase and tensin homolog-null tumors. Thus, this study tested the combination of mTOR inhibition (everolimus) and epidermal growth factor receptor inhibition (gefitinib) in castration-resistant prostate cancer (CRPC).In phase 1, 12 patients (10 with CRPC and 2 with glioblastoma) received daily gefitinib (250 mg) with weekly everolimus (30, 50, or 70 mg). In phase 2, 27 CRPC patients received gefitinib with everolimus (70 mg).Phase 1 revealed no pharmacokinetic interactions and no dose-limiting toxicities. In phase 2, 18 of 27 patients (67%) discontinued treatment before the 12-week evaluation because of progression as evidenced by prostate-specific antigen (PSA) levels (n = 6) or imaging (n = 5) or because of a grade 2 or higher toxicity (n = 7). Thirteen of the 37 CRPC patients (35%) exhibited a rapidly rising PSA level after they had begun treatment, and this declined upon discontinuation. Fluorodeoxyglucose positron emission tomography 24 to 72 hours after the initiation of treatment showed a decrease in the standardized uptake value consistent with mTOR inhibition in 27 of the 33 evaluable patients (82%); there was a corresponding rise in PSA in 20 of these 27 patients (74%).The combination of gefitinib and everolimus did not result in significant antitumor activity. The induction of PSA in tumors treated with mTOR inhibitors was consistent with preclinical data showing that phosphoinositide 3-kinase (PI3K) pathway signaling feedback inhibits the androgen receptor (AR). This clinical evidence of relief of feedback inhibition promoting enhanced AR activity supports future studies combining PI3K pathway inhibitors and second-generation AR inhibitors in CRPC." @default.
• W2116995045 created "2016-06-24" @default.
• W2116995045 creator A5002358672 @default.
• W2116995045 creator A5015396908 @default.
• W2116995045 creator A5017288060 @default.
• W2116995045 creator A5031035765 @default.
• W2116995045 creator A5039147214 @default.
• W2116995045 creator A5042883465 @default.
• W2116995045 creator A5055433546 @default.
• W2116995045 creator A5059546521 @default.
• W2116995045 creator A5060228803 @default.
• W2116995045 creator A5072850546 @default.
• W2116995045 date "2015-07-15" @default.
• W2116995045 modified "2023-10-05" @default.
• W2116995045 title "Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications" @default.
• W2116995045 cites W1797430954 @default.
• W2116995045 cites W1978916359 @default.
• W2116995045 cites W1988609792 @default.
• W2116995045 cites W1991528292 @default.
• W2116995045 cites W2019789647 @default.
• W2116995045 cites W2068480412 @default.
• W2116995045 cites W2069032457 @default.
• W2116995045 cites W2071665742 @default.
• W2116995045 cites W2073100248 @default.
• W2116995045 cites W2086382688 @default.
• W2116995045 cites W2102103107 @default.
• W2116995045 cites W2102648794 @default.
• W2116995045 cites W2107633226 @default.
• W2116995045 cites W2108549165 @default.
• W2116995045 cites W2126783165 @default.
• W2116995045 cites W2139248078 @default.
• W2116995045 cites W2145517536 @default.
• W2116995045 cites W2149218373 @default.
• W2116995045 cites W2149246783 @default.
• W2116995045 cites W2155228605 @default.
• W2116995045 cites W2160363302 @default.
• W2116995045 cites W2164895949 @default.
• W2116995045 cites W2165300664 @default.
• W2116995045 cites W2167331614 @default.
• W2116995045 cites W2170316270 @default.
• W2116995045 doi "https://doi.org/10.1002/cncr.29578" @default.
• W2116995045 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4618268" @default.
• W2116995045 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26178426" @default.
• W2116995045 hasPublicationYear "2015" @default.
• W2116995045 type Work @default.
• W2116995045 sameAs 2116995045 @default.
• W2116995045 citedByCount "24" @default.
• W2116995045 countsByYear W21169950452016 @default.
• W2116995045 countsByYear W21169950452017 @default.
• W2116995045 countsByYear W21169950452018 @default.
• W2116995045 countsByYear W21169950452019 @default.
• W2116995045 countsByYear W21169950452020 @default.
• W2116995045 countsByYear W21169950452021 @default.
• W2116995045 countsByYear W21169950452022 @default.
• W2116995045 countsByYear W21169950452023 @default.
• W2116995045 crossrefType "journal-article" @default.
• W2116995045 hasAuthorship W2116995045A5002358672 @default.
• W2116995045 hasAuthorship W2116995045A5015396908 @default.
• W2116995045 hasAuthorship W2116995045A5017288060 @default.
• W2116995045 hasAuthorship W2116995045A5031035765 @default.
• W2116995045 hasAuthorship W2116995045A5039147214 @default.
• W2116995045 hasAuthorship W2116995045A5042883465 @default.
• W2116995045 hasAuthorship W2116995045A5055433546 @default.
• W2116995045 hasAuthorship W2116995045A5059546521 @default.
• W2116995045 hasAuthorship W2116995045A5060228803 @default.
• W2116995045 hasAuthorship W2116995045A5072850546 @default.
• W2116995045 hasBestOaLocation W21169950451 @default.
• W2116995045 hasConcept C121608353 @default.
• W2116995045 hasConcept C126322002 @default.
• W2116995045 hasConcept C143998085 @default.
• W2116995045 hasConcept C2779438470 @default.
• W2116995045 hasConcept C2779699572 @default.
• W2116995045 hasConcept C2780192828 @default.
• W2116995045 hasConcept C2780580887 @default.
• W2116995045 hasConcept C502942594 @default.
• W2116995045 hasConcept C55493867 @default.
• W2116995045 hasConcept C61367390 @default.
• W2116995045 hasConcept C62478195 @default.
• W2116995045 hasConcept C71924100 @default.
• W2116995045 hasConcept C86554907 @default.
• W2116995045 hasConcept C86803240 @default.
• W2116995045 hasConcept C98274493 @default.
• W2116995045 hasConceptScore W2116995045C121608353 @default.
• W2116995045 hasConceptScore W2116995045C126322002 @default.
• W2116995045 hasConceptScore W2116995045C143998085 @default.
• W2116995045 hasConceptScore W2116995045C2779438470 @default.
• W2116995045 hasConceptScore W2116995045C2779699572 @default.
• W2116995045 hasConceptScore W2116995045C2780192828 @default.
• W2116995045 hasConceptScore W2116995045C2780580887 @default.
• W2116995045 hasConceptScore W2116995045C502942594 @default.
• W2116995045 hasConceptScore W2116995045C55493867 @default.
• W2116995045 hasConceptScore W2116995045C61367390 @default.
• W2116995045 hasConceptScore W2116995045C62478195 @default.
• W2116995045 hasConceptScore W2116995045C71924100 @default.
• W2116995045 hasConceptScore W2116995045C86554907 @default.
• W2116995045 hasConceptScore W2116995045C86803240 @default.
• W2116995045 hasConceptScore W2116995045C98274493 @default.
• W2116995045 hasFunder F4320306163 @default.

• next